title: [Peyronie's disease: comparative results of conservative treatment].
abstract: Long-term clinical experience with conservative treatment of Peyronie's disease has demonstrated that clinical efficacy of this therapy comprises maily anesthesia while erectile problems are not solved. Introduction of the drugs into the fibrous plaque is not adequate and hard to perform. Some drugs affect only some components of pathogenesis. For stabilization of the process it is recommended to use transdermal electrophoresis or phonophoresis. The search for new effective drugs and methods continues.
authors.forename: V A
authors.initials: VA
authors.lastname: Kovalev
authors.forename: S K
authors.initials: SK
authors.lastname: Karaguzhin
authors.forename: A N
authors.initials: AN
authors.lastname: Abdulkhamidov
authors.forename: V M
authors.initials: VM
authors.lastname: Danovich
authors.forename: P S
authors.initials: PS
authors.lastname: Kyzlasov
authors.forename: S V
authors.initials: SV
authors.lastname: Matskevich
mesh_terms: D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D018274:Electroporation; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000517:prevention & control; D010411:Penile Induration / Q000188:drug therapy*; D015612:Phonophoresis; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*; D014971:Xanthinol Niacinate / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000305:Adrenal Cortex Hormones; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014971:Xanthinol Niacinate; D014700:Verapamil